perplexity

The Relationship Between Hydroxychloroquine and Vitamin D Metabolism

Hydroxychloroquine (HCQ) is a medication commonly used in the treatment of various autoimmune conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and malaria. The relationship between HCQ and vitamin D metabolism is complex and involves several pathways that affect vitamin D bioavailability and activity. Based on current evidence, HCQ appears to inhibit rather than increase vitamin D levels or vitamin D receptor activation.

Inhibitory Effects of HCQ on Vitamin D Metabolism

Research indicates that hydroxychloroquine inhibits the conversion of 25-hydroxyvitamin D (25(OH)D) to 1,25-dihydroxyvitamin D (1,25(OH)2D), which is the biologically active form of vitamin D. This inhibition has been observed both in laboratory studies and in clinical settings, particularly in patients with certain conditions.

A clinical study investigating vitamin D levels in women with systemic lupus erythematosus (SLE) and fibromyalgia found that HCQ users had significantly lower 1,25(OH)2-vitamin D levels compared to non-users. The mean adjusted difference was 24.4 pmol/l (95% CI 2.8-49.9), suggesting that HCQ might inhibit the conversion of 25(OH)-vitamin D to its active form in these patients[1]. The researchers concluded that this inhibitory effect of HCQ on vitamin D activation could be clinically significant.

Further evidence of this relationship comes from a study examining patients with Q fever endocarditis who were treated with a combination of doxycycline and hydroxychloroquine. These patients demonstrated significantly lower vitamin D levels compared to controls. Moreover, the duration of treatment was also a factor, as patients receiving treatment for more than three months presented significantly lower vitamin D levels than those treated for less than three months[2]. This finding suggests that prolonged HCQ treatment may progressively reduce vitamin D levels over time.

Mechanisms of HCQ's Effects on Vitamin D

The mechanisms behind HCQ's inhibitory effects on vitamin D metabolism are not fully understood, but several pathways have been proposed. HCQ is a weak base that accumulates in acidic compartments such as lysosomes and inflamed tissues[3]. This accumulation raises the pH in these compartments, which may interfere with various enzymatic activities, including those involved in vitamin D metabolism.

Vitamin D metabolism involves several hydroxylation steps. To become biologically active, vitamin D undergoes enzymatic conversions through hydroxylation to initially convert to 25(OH)D, and then primarily in the kidneys, the enzyme 1α-hydroxylase (CYP27B1) produces

1,25(OH)2D, the active form of vitamin D[4]. HCQ might interfere with these enzymatic processes, particularly the final activation step catalyzed by CYP27B1.

Additionally, it's known that HCQ can disrupt the normal functioning of lysosomes by increasing their pH, which impairs various enzymatic activities. Since vitamin D metabolism involves enzymes that may be sensitive to pH changes, this lysosomal dysfunction could contribute to the inhibition of vitamin D activation[5].

Clinical Implications

The inhibitory effect of HCQ on vitamin D metabolism has important clinical implications, particularly for patients with autoimmune conditions who are often prescribed HCQ as part of their treatment regimen. These patients might be at higher risk of vitamin D deficiency, which has been associated with various health issues including increased cardiovascular disease risk, metabolic syndrome, and type 2 diabetes[2].

For SLE patients, the situation is particularly concerning since many already spend less time exposed to sunlight due to photosensitivity, potentially leading to lower baseline vitamin D levels. In one study, half of SLE patients had 25(OH)-vitamin D levels below 50 nmol/l, a level at which parathyroid hormone stimulation occurs[1]. Adding HCQ to their treatment regimen might further reduce their active vitamin D levels.

Potential Synergistic Effects

Despite the inhibitory effect of HCQ on vitamin D metabolism, some studies suggest potential synergistic effects between vitamin D supplementation and HCQ in certain clinical scenarios. In cases of refractory immune thrombocytopenia, patients' platelet counts significantly increased with combined vitamin D and hydroxychloroquine treatment, but decreased upon vitamin D discontinuation[6]. This suggests that while HCQ may reduce endogenous active vitamin D levels, supplementing with vitamin D alongside HCQ treatment might provide complementary therapeutic benefits.

This synergism might be explained by overlapping immunomodulatory effects. Both vitamin D and HCQ have anti-inflammatory properties and can modulate immune responses through various pathways. Vitamin D has been shown to reduce the production of pro-inflammatory cytokines, inhibit T-cell proliferation, and promote T regulatory cells[7]. Similarly, HCQ inhibits antigen presentation, reduces the release of cytokines like interleukin-1 and tumor necrosis factor, and may inhibit Toll-like receptors[8].

Future Research Directions

The complex relationship between HCQ and vitamin D metabolism warrants further investigation. Future studies should focus on several key areas:

1. Determining the precise molecular mechanisms by which HCQ inhibits vitamin D activation.
2. Evaluating whether vitamin D supplementation should be routinely recommended for patients on long-term HCQ therapy.

3. Investigating the potential synergistic effects of combined HCQ and vitamin D therapy in various autoimmune conditions.
4. Assessing whether different dosing regimens of HCQ have varying effects on vitamin D metabolism.

Conclusion

Based on the available evidence, hydroxychloroquine does not increase vitamin D levels or enhance vitamin D receptor activation. Instead, it appears to inhibit the conversion of 25(OH)-vitamin D to its active form, 1,25(OH)2-vitamin D, potentially leading to reduced vitamin D activity. This effect is particularly significant in patients with conditions like SLE who may already have compromised vitamin D status due to reduced sun exposure. While there may be synergistic therapeutic effects between vitamin D supplementation and HCQ in certain conditions, this does not negate the underlying inhibitory effect of HCQ on vitamin D metabolism. Healthcare providers should consider monitoring vitamin D status in patients on long-term HCQ therapy and recommend appropriate supplementation when necessary.

⁂

1. https://pubmed.ncbi.nlm.nih.gov/11708429/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3837883/
3. https://www.oaepublish.com/articles/2574-1209.2023.142
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7447609/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC9787624/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3623781/
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7146294/
8. https://go.drugbank.com/drugs/DB01611